Stroma-epithelium crosstalk in prostate cancer

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 28-35

  Niu, Yi Nong ^a   Xia, Shu Jie ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANDROGEN; CALPONIN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GLUTATHIONE TRANSFERASE; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; RETINOIC ACID RECEPTOR BETA; SCATTER FACTOR RECEPTOR; SCLEROPROTEIN; SEPRASE; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VASCULOTROPIN;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL INTERACTION; CELL TRANSDIFFERENTIATION; CYTOKINE RELEASE; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION; CELL COMMUNICATION; DISEASE COURSE; MALE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

CELL COMMUNICATION; DISEASE PROGRESSION; EPITHELIAL CELLS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK; STROMAL CELLS;

EID: 69449095475     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.39     Document Type: Review

References (79)

1. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
2. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-7.
3. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008; 18: 27-34.
4. West RB, van de Rijn M. Experimental approaches to the study of cancer-stroma interactions: Recent findings suggest a pivotal role for stroma in carcinogenesis. Lab Invest 2007; 87: 967-70.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
6. Condon MS. The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol 2005; 15: 132-7.
7. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65: 8887-95.
8. Arnold JT, Gray NE, Jacobowitz K, Viswanathan L, Cheung PW, et al. Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J Steroid Biochem Mol Biol 2008; 111: 240-6.
9. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007; 101: 873-86.
10. Berry PA, Maitland NJ, Collins AT. Androgen receptor signalling in prostate: Effects of stromal factors on normal and cancer stem cells. Mol Cell Endocrinol 2008; 288: 30-7.
11. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-47.
12. Zhang Y, Nojima S, Nakayama H, Jin Y, Enza H. Characteristics of normal stromal components and their correlation with cancer occurrence in human prostate. Oncol Rep 2003; 10: 207-11.
13. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, et al. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8: 2912-23.
14. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993; 13: 4513-22.
15. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY, et al. Coinoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer 1989; 43: 1179-87.
16. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-11.
17. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001; 61: 8135-42.
18. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-11.
19. Bierie B, Moses HL. Under pressure: Stromal fibroblasts change their ways. Cell 2005; 123: 985-7.
20. Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC, et al. Can cancer cells transform normal host cells into malignant cells? Br J Cancer 1997; 76: 1134-8.
21. Macintosh CA, Stower M, Reid N, Maitland NJ. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 1998; 58: 23-8.
22. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006; 98: 255-61.
23. Rodriguez-Canales J, Hanson JC, Tangrea MA, Erickson HS, Albert PS, et al. Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol 2007; 211: 410-9.
24. Cano P, Godoy A, Escamilla R, Dhir R, Onate SA. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Res 2007; 67: 511-9.
25. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005; 63: 19-28.
26. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 2001; 61: 423-7.
27. Wikström P, Ohlson N, Stattin P, Bergh A. Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy. Prostate 2007; 67: 1277-84.
28. Ingber DE. Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. Differentiation 2002; 70: 547-60.
29. Ghersi G. Roles of molecules involved in epithelial/mesenchymal transition during angiogenesis. Front Biosci 2008; 13: 2335-55.
30. Jin H, Varner J. Integrins: Roles in cancer development and as treatment targets. Br J Cancer 2004; 90: 561-5.
31. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-26.
32. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF, Schalken JA. Complex cadherin expression in human prostate cancer cells. Int J Cancer 2000; 85: 446-50.
33. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000; 60: 3650-4.
34. Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008; 47: 1076-86.
35. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 2005; 173: 10-20.
36. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-51.
37. Ao M, Williams K, Bhowmick NA, Hayward SW. Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 2006; 66: 8007-16.
38. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 2005; 41: 846-57.
39. Bello-DeOcampo D, Tindall DJ. TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets 2003; 4: 197-207.
40. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 2003; 5: 267-77.
41. Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, et al. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer 2005; 104: 44-52.
42. Pulukuri SM, Rao JS. CpG island promoter methylation and silencing of 14-3-3 sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene 2006; 25: 4559-72.
43. Gerdes MJ, Larsen M, Dang TD, Ressler SJ, Tuxhorn JA, et al. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1. Prostate 2004; 58: 299-307.
44. Song K, Wang H, Krebs TL, Kim SJ, Danielpour D. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res 2008; 68: 8173-82.
45. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 2005; 11: 4512-20.
46. Story MT, Hopp KA, Meier DA. Regulation of basic fibroblast growth factor expression by transforming growth factor beta in cultured human prostate stromal cells. Prostate 1996; 28: 219-26.
47. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, et al. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 2004; 101: 7112-7.
48. Chen SJ, Karan D, Johansson SL, Lin FF, Zeckser J, et al. Prostate derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 2007; 67: 557-71.
49. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 1998; 139: 4672-8.
50. Muir C, Chung LW, Carson DD, Farach-Carson MC. Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Clin Exp Metastasis 2006; 23: 75-86.
51. Jennbacken K, Vallbo C, Wang W, Damber JE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65: 110-6.
52. Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, et al. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res 2004; 24: 2135-40.
53. Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 2007; 67: 84-90.
54. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 2002; 398: 284-90.
55. Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, et al. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008; 26: 1425-35.
56. Johansson A, Jones J, Pietras K, Kilter S, Skytt A, et al. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate 2007; 67: 1664-76.
57. Li W, Wu CL, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 2007; 171: 1189-98.
58. Saikali Z, Setya H, Singh G, Persad S. Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int 2008; 8: 10.
59. York TP, Plymate SR, Nelson PS, Eaves LJ, Webb HD, et al. cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostate epithelial cells. Mol Carcinog 2005; 44: 242-51.
60. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, et al. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006; 99: 392-401.
61. Ohlson N, Bergh A, Stattin P, Wikström P. Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate 2007; 67: 32-40.
62. Montagnani Marelli M, Moretti RM, Mai S, Procacci P, Limonta P. Gonadotropin releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 2007; 30: 261-71.
63. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004; 91: 31-67.
64. Verras M, Lee J, Xue H, Li TH, Wang Y, et al. The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression. Cancer Res 2007; 67: 967-75.
65. Ye L, Lewis-Russell JM, Sanders AJ, Kynaston H, Jiang WG. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urol Oncol 2008; 26: 190-7.
66. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008; 17: 997-1011.
67. Maeda A, Nakashiro K, Hara S, Sasaki T, Miwa Y, et al. Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun 2006; 347: 1158-65.
68. Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, et al. Met-independent hepatocyte growth factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer 2006; 6: 197.
69. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11: 709-24.
70. Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, et al Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005; 93: 964-75.
71. Oosterhoff JK, Grootegoed JA, Blok LJ. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling. Endocr Relat Cancer 2005; 12: 135-48.
72. Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 2004; 112: 78-86.
73. Wang J, Wang J, Sun Y, Song W, Nor JE, et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 2005; 17: 1578-92.
74. Sun YX, Schneider A, Jung Y, Wang J, Dai J, et al. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20: 318-29.
75. Ao M, Franco OE, Park D, Raman D, Williams K, et al. Crosstalk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 2007; 67: 4244-53.
76. Burger JA, Kipps TJ. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-7.
77. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95: 497-505.
78. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007; 67: 764-73.
79. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006; 66: 3087-95.